No Data
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25
Cabaletta Bio's Promising Clinical Progress and Strong Buy Rating by Douglas Tsao
Cabaletta Bio's Rese-cel Shows Efficacy in Clinical Studies
Express News | Cabaletta Bio Announces Updated Clinical Data From First Patients Dosed With Rese-cel; Says 90% Of Patients Experienced Either No CRS Or Grade 1 CRS And 0-% Experienced No ICANS
Express News | Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses Across Multiple Indications With Rese-Cel at February Scientific Meetings
